CN114599371A - 作为癌症靶向药物载体的磷脂醚缀合物 - Google Patents

作为癌症靶向药物载体的磷脂醚缀合物 Download PDF

Info

Publication number
CN114599371A
CN114599371A CN202080074564.3A CN202080074564A CN114599371A CN 114599371 A CN114599371 A CN 114599371A CN 202080074564 A CN202080074564 A CN 202080074564A CN 114599371 A CN114599371 A CN 114599371A
Authority
CN
China
Prior art keywords
cancer
compound
pharmaceutically acceptable
melanoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080074564.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·隆科尔
A·平丘克
R·胡佛
黄中平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectar Biosciences Inc
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of CN114599371A publication Critical patent/CN114599371A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202080074564.3A 2019-09-12 2020-09-11 作为癌症靶向药物载体的磷脂醚缀合物 Pending CN114599371A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962899615P 2019-09-12 2019-09-12
US201962899611P 2019-09-12 2019-09-12
US201962899618P 2019-09-12 2019-09-12
US62/899,611 2019-09-12
US62/899,618 2019-09-12
US62/899,615 2019-09-12
US201962946870P 2019-12-11 2019-12-11
US62/946,870 2019-12-11
US202062956844P 2020-01-03 2020-01-03
US202062956907P 2020-01-03 2020-01-03
US62/956,844 2020-01-03
US62/956,907 2020-01-03
PCT/US2020/050459 WO2021050917A1 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Publications (1)

Publication Number Publication Date
CN114599371A true CN114599371A (zh) 2022-06-07

Family

ID=74866023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074564.3A Pending CN114599371A (zh) 2019-09-12 2020-09-11 作为癌症靶向药物载体的磷脂醚缀合物

Country Status (11)

Country Link
US (1) US20230066517A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028018A4 (cg-RX-API-DMAC7.html)
JP (3) JP7749542B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062363A (cg-RX-API-DMAC7.html)
CN (1) CN114599371A (cg-RX-API-DMAC7.html)
AU (2) AU2020346898B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150991A1 (cg-RX-API-DMAC7.html)
IL (1) IL291197A (cg-RX-API-DMAC7.html)
MX (1) MX2022003044A (cg-RX-API-DMAC7.html)
WO (1) WO2021050917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200017A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
KR102973364B1 (ko) * 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
CN113816990B (zh) * 2021-03-22 2023-08-22 联宁(苏州)生物制药有限公司 修饰的氨基酸及其在adc中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020178A1 (en) * 2004-03-02 2007-01-25 Cellectar, Llc Phospholipid ether analogs as cancer treatment agents and methods thereof
US20110064661A1 (en) * 2009-09-11 2011-03-17 Pinchuk Anatoly Non-radioactive phospholipid compounds, compositions, and methods of use
US20170356914A1 (en) * 2016-06-14 2017-12-14 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310702A (zh) * 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
WO2019200017A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020178A1 (en) * 2004-03-02 2007-01-25 Cellectar, Llc Phospholipid ether analogs as cancer treatment agents and methods thereof
US20110064661A1 (en) * 2009-09-11 2011-03-17 Pinchuk Anatoly Non-radioactive phospholipid compounds, compositions, and methods of use
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
US20170356914A1 (en) * 2016-06-14 2017-12-14 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
CN109791152A (zh) * 2016-06-14 2019-05-21 塞勒科塔生物科学公司 用于鉴定和分离循环肿瘤细胞的磷脂醚类似物

Also Published As

Publication number Publication date
AU2020346898A1 (en) 2022-04-07
JP2025138792A (ja) 2025-09-25
JP2022547331A (ja) 2022-11-11
BR112022004482A2 (pt) 2022-05-31
AU2020346898B2 (en) 2026-04-09
JP7749542B2 (ja) 2025-10-06
AU2026204469A1 (en) 2026-06-25
WO2021050917A1 (en) 2021-03-18
IL291197A (en) 2022-05-01
EP4028018A1 (en) 2022-07-20
KR20220062363A (ko) 2022-05-16
MX2022003044A (es) 2022-06-02
JP2025087716A (ja) 2025-06-10
EP4028018A4 (en) 2023-10-11
NZ786360A (en) 2025-12-19
US20230066517A1 (en) 2023-03-02
CA3150991A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US11439709B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
JP7749542B2 (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
US11572379B2 (en) Monomaleimide-functionalized platinum compounds for cancer therapy
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
JP2024511466A (ja) Alk-5阻害剤及びその使用
JP7566010B2 (ja) 四環式化合物及びそれらの塩、組成物、ならびにそれらの使用方法
CN121127460A (zh) 可用作治疗剂的新型化合物
HK40075720A (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
HK40042533A (en) Phospholipid ether analogs as cancer-targeting drug vehicles
HK40042533B (en) Phospholipid ether analogs as cancer-targeting drug vehicles
NZ731669B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
HK40031549B (en) Compounds and compositions for treating hematological disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075720

Country of ref document: HK